News Sentiment

TTRX sentiment intelligence

Turn Therapeutics Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 5.87 Week of 19 Jun 2026
Weighted tone 60/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-2.9% over one week, +14.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Turn Therapeutics Ord Shs (TTRX) Institutional Confidence

Market Reaction

Balanced read

69/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction -2.9% Price reacting lower
Trend fit Trend active 14.4% over four weeks
Fair value 40.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 35
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
TradingKey 9
Market source 6
TradingView 5
MarketBeat 4
Business Wire 3
simplywall.st 3
Stocktwits 2
Stock Titan 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 20
Regulatory and legal 7
Analyst action 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
Business Wire Direct company coverage

Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Turn Therapeutics reported its First Quarter 2026 financial results, highlighting a strengthened financial position due to a $7 million initial funding tranche from Avenue Capital Group. The company is advancing its Phase 2 clinical trial for GX-03 in moderate-to-severe atopic de

Tone
Positive 74/100
Event
Earnings
Published
11 May 2026 20:10
Source
Business Wire
MarketBeat Direct company coverage

Turn Therapeutics (NASDAQ:TTRX) Trading 6% Higher - Should You Buy?

Turn Therapeutics (NASDAQ:TTRX) saw its stock price rise by 6% on Friday, trading at $3.55, although with light trading volume. Analysts have a "Hold" rating on the stock, with an average price target of $8.00, stemming from one "Buy" rating and one "Sell" rating. The company, a

Tone
Neutral 50/100
Event
Analyst action
Published
25 Apr 2026 06:39
Source
MarketBeat
MEXC Direct company coverage

TTRX Price Today: Turn Therapeutics Inc. Stock Price, Quote & Chart | MEXC

This article provides current and historical stock performance data for Turn Therapeutics Inc. (TTRX), a clinical-stage biotechnology and medical device development company. It details key market data, price changes, and investment insights, along with a guide on how to buy TTRX

Tone
Neutral 50/100
Event
Market update
Published
24 Apr 2026 15:10
Source
MEXC
Quantisnow Direct company coverage

Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

Turn Therapeutics reported its full-year 2025 financial results and provided corporate updates. The announcement was made via a press release disseminated through Quantisnow, a real-time market data platform for retail investors. Quantisnow Plus members received an alert shortly

Tone
Neutral 50/100
Event
Earnings
Published
11 Apr 2026 08:40
Source
Quantisnow
Market source Direct company coverage

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group

Turn Therapeutics, a clinical-stage dermatology company, has secured up to $25 million in growth capital financing from Avenue Venture Opportunities Fund II, L.P. An initial $7 million has been funded, with the remaining $18 million contingent on achieving clinical and corporate

Tone
Positive 80/100
Event
Market update
Published
10 Apr 2026 20:39
Source
Market source
Stock Titan Direct company coverage

Turn Therapeutics (TTRX) CEO-linked entity gifts 300,000 shares, retains 15.7M

Turn Therapeutics Inc. CEO Burnam Bradley Evan, through his controlled entity BEB Holdings, LLC, reported a bona fide gift of 300,000 shares of common stock at a price of $0.00 per share. This transaction was identified as a non-cash, routine disposition, not a market sale, and l

Tone
Neutral 50/100
Event
Market update
Published
08 Apr 2026 19:40
Source
Stock Titan